<?xml version="1.0" encoding="UTF-8"?>
<p id="Par26">In vitro neural development was impaired in neural lines derived from patients carrying 
 <italic>LRRK2, PRKN, SNCA</italic>, and sporadic mutations
 <sup>
  <xref ref-type="bibr" rid="CR43">43</xref>,
  <xref ref-type="bibr" rid="CR49">49</xref>,
  <xref ref-type="bibr" rid="CR74">74</xref>,
  <xref ref-type="bibr" rid="CR93">93</xref>
 </sup>. In four independent studies, the differentiation potential of neural progenitor cells derived from patients was significantly reduced, demonstrated by low yields of neurons in comparison with control lines
 <sup>
  <xref ref-type="bibr" rid="CR43">43</xref>,
  <xref ref-type="bibr" rid="CR49">49</xref>,
  <xref ref-type="bibr" rid="CR74">74</xref>,
  <xref ref-type="bibr" rid="CR81">81</xref>,
  <xref ref-type="bibr" rid="CR94">94</xref>
 </sup>. A recent review presented the idea that PD is attributed to significant neurodevelopmental defects, which may increase the susceptibility for disease onset
 <sup>
  <xref ref-type="bibr" rid="CR224">224</xref>
 </sup>. If confirmed, identifying genetic predispositions that contribute to early developmental defects in iPSC-PD may assist the development of novel PD therapies. However, these phenotypes may appear in conflict with other studies
 <sup>
  <xref ref-type="bibr" rid="CR53">53</xref>,
  <xref ref-type="bibr" rid="CR55">55</xref>,
  <xref ref-type="bibr" rid="CR76">76</xref>
 </sup> capable of generating functional neurons from cell lines with similar mutations. The differences could be due to varying protocols, which may be more or less stressful for the cells.
</p>
